About Sylentis
Sylentis is a Healthcare company based in Tres Cantos (Spain) founded in 2006. SiRNA-based formulations for eye disease treatments are developed. It operates in the Healthcare and Technology sectors. Sylentis offers products and services including SirFinder TM, Tivanisiran, and SYL1801. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its legal entity is Sylentis, S.A.
Company details
Developer of siRNA-based formulations for the treatment of eye diseases. The companys drug pipeline includes Bamosiran a small interference RNA (siRNA) inhibitor of beta 2 adrenergic receptor for the treatment of Glaucoma, SYL1001 siRNA inhibitor of the Transient Receptor Potential Vanilloid-1 (TRPV1)) for the treatment of dry eye syndrome- ocular pain. Other drug candidates are for ocular allergies, Crohns, arthritis, dementia, and others.
- Headquarters Tres Cantos, Spain
- SectorsHealthcareTechnology
- Email••••••••
- Phone•••• ••••
- Website sylentis.com
- Social LinkedIn
- Legal Name Sylentis, S.A.
- Latest Funding Round$709.2K (USD), Grant
Jun 2021
- Investors
Products & Services of Sylentis
Sylentis offers a comprehensive portfolio of products and services, including SirFinder TM, Tivanisiran, and SYL1801.
Software for designing efficient siRNA compounds for gene silencing
RNAi-based treatment targeting dry eye syndrome effectively
RNAi compound for retinal disease management and therapy
Funding Insights of Sylentis
- Total Rounds 2
- Last Round Grant — $709,201
- First Round $777,441
(Jan 2015)
- Investors Count 1
All 2 funding rounds of Sylentis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | $709,201 | Grant | – | – | |
| Jan 2015 | $777,441 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Sylentis
Sylentis has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Sylentis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Sylentis
3 dated milestones of Sylentis across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Sylentis is founded.
- Funding First funding round of $777K.
- Funding Latest funding round, Grant, of $709K.
Web traffic of Sylentis
The website of Sylentis (sylentis.com) receives about 3.9K visits a month.
- Monthly visits3.9K
▼ 3% vs previous month
Websites whose visitors overlap most with Sylentis. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| silence-therapeutics.com | 100% | 13.8K | #1,916,504 | View details | |
cenix-bioscience.com | cenix-bioscience.com | 97% | – | ||
| cequentpharma.com | 97% | View details | |||
| calandopharma.com | 87% | #10,840,843 | View details | ||
| armagen.com | 87% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 21 similar websites and full traffic analytics for Sylentis
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 21 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sylentis
Complete news archive for Sylentis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sylentis
Sylentis was founded in 2006 and raised its 1st funding round 9 years after it was founded.
Sylentis is headquartered in Tres Cantos, Spain. It is registered at Tres Cantos, Madrid, Spain.
Developer of siRNA-based formulations for the treatment of eye diseases. The companys drug pipeline includes Bamosiran a small interference RNA (siRNA) inhibitor of beta 2 adrenergic receptor for the treatment of Glaucoma, SYL1001 siRNA inhibitor of the Transient Receptor Potential Vanilloid-1 (TRPV1)) for the treatment of dry eye syndrome- ocular pain. Other drug candidates are for ocular allergies, Crohns, arthritis, dementia, and others.
Sylentis offers SirFinder TM, Tivanisiran, and SYL1801.
Sylentis has 1 investor. Key investors include European Union.
Sylentis operates through Sylentis, S.A..